Table 2 Kaplan-Meier estimates for the association of tumor factors with OS in patients with cervical sarcoma who received surgical treatment (n = 30)
From: Sarcoma of the uterine cervix: experience of a single center
Clinical Characteristics | Cervical sarcoma | 5-year OS | P | |
|---|---|---|---|---|
n | % | |||
Age (years) | 0.845 | |||
<40 | 15 | 50.0 | 64.0% | |
≥40 | 15 | 50.0 | 64.6% | |
Tumor size (cm) | 0.291 | |||
<5 | 14 | 46.7 | 76.0% | |
≥ 5 | 16 | 53.3 | 54.1% | |
Pathologic Stage (FIGO 2018) | 0.903 | |||
I-II | 24 | 80.0 | 64.9% | |
III-IV | 6 | 20.0 | 62.5% | |
Neoadjuvant chemotherapy | 0.001 | |||
Yes | 7 | 23.3 | 21.4% | |
No | 23 | 76.7 | 76.6% | |
Surgery type | 0.910 | |||
Radical hysterectomy | 14 | 46.7 | 62.9% | |
Hysterectomy or tumor resection | 16 | 53.3 | 66.5% | |
Cervical stromal invasion | 0.250 | |||
Inner 2/3 | 11 | 39.3 | 79.5% | |
Outer 1/3 | 17 | 60.7 | 50.5% | |
NA | 2 | |||
Lymphvascular space invasion | 0.831 | |||
Positive | 18 | 62.1 | 54.5% | |
Negative | 11 | 37.9 | 59.1% | |
NA | 1 | |||
Pelvic/para-aortic lymph node | 0.462 | |||
Positive | 4 | 28.6 | 66.7% | |
Negative | 10 | 71.4 | 60.0% | |
NA | 16 | |||
Adjuvant chemotherapy | 0.269 | |||
Yes | 21 | 70.0 | 53.9% | |
No | 9 | 30.0 | 88.9% | |
Adjuvant radiotherapy | 0.838 | |||
Yes | 4 | 13.3 | 75.0% | |
No | 26 | 86.7 | 64.4% | |